![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Transdermal contraceptive patches were first introduced in the USA in the spring of 2002. Approval in Canada and the EU followed soon thereafter. In the USA, sales of the patch were so robust that during the first months the manufacturer could not keep up with demand; by fall of 2002, the patch was the second highest selling combined hormonal contraceptive in the USA. This initial success reflected the strong demand that US women had for a more convenient delivery system that required less frequent dosing. Adolescent women in particular seemed to be more able to successfully use patches than they did pills. However, following a typical US pattern of boom-and-bust cycling and the initiation of litigation that claimed that there was a greater risk of venous thromboembolism (VTE) with the patch, sales in the USA dropped significantly. This article describes the hormonal properties of the contraceptive patches that are currently available, the clinical experience with the patch, and the results of postmarketing surveillance for VTE. We also discuss the potential for future contraceptive products using this route of administration.
Financial & competing interests disclosure
Anita Nelson has received a research grant from Bayer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.